Aiolos Bio

📍 San Francisco, United States🗓 Founded 2023👥 3 employees💰 Last funded Jul 2023
Biotechnology Research🌐 AiolosBio.com
Website LinkedIn
At Aiolos Bio, we are dedicated to revolutionizing the treatment landscape for respiratory disease and other immunological disorders. Our goal is to provide patients and caregivers with more efficacious therapies that significantly reduce treatment burden. Our vision is embodied in our current focus – the development of a groundbreaking anti-TSLP therapy with best-in-class potential. We are a San Francisco Bay area-based clinical stage biopharma company with additional operations in London, UK. The Aiolos team is comprised of seasoned drug developers, who have successfully developed and launched products for a range of immune conditions, including asthma, rheumatoid arthritis, IPF, and more. As we grow, we will look to add like-minded individuals to our team - those committed to the goal of providing a meaningful difference in the lives of patients suffering from respiratory illnesses and other immune disorders.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2023
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
1
Frequently asked questions
Who invested in Aiolos Bio?
Aiolos Bio has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Aiolos Bio last raise funding?
The most recent investment in Aiolos Bio recorded on gritt.io was in July 2023.
When was Aiolos Bio founded?
Aiolos Bio was founded in 2023.
What industry is Aiolos Bio in?
Aiolos Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Aiolos Bio based?
Aiolos Bio is headquartered in San Francisco, United States.